KLOW
Cambrian blend: GHK-Cu + BPC-157 + TB-500 + KPV. Evidence must be assessed component-by-component.
Mechanism & research rationale
KLOW combines four compounds with different proposed research pathways: GHK-Cu (copper/matrix signalling), BPC-157 (preclinical repair and nitric-oxide/angiogenic pathways), TB-500/thymosin-related signalling (actin/cell migration context) and KPV (an α-MSH-derived tripeptide investigated for anti-inflammatory signalling). There is no scientific basis to assume the effects of the components simply add together.
Human evidence
No controlled human study of the KLOW blend was identified. Human evidence for BPC-157, TB-500 and GHK-Cu is limited or indirect, while KPV evidence is predominantly cellular and animal. Any claims about the blend therefore need to remain explicitly exploratory.
Preclinical / translational evidence
KPV has been investigated in intestinal epithelial/immune-cell systems and mouse colitis models, including effects involving PepT1 uptake and inflammatory signalling. The other three components have separate preclinical literatures summarized elsewhere in this library.
Key limitations
- No blend-specific pharmacokinetic, interaction or safety studies were identified.
- Component findings cannot be summed to predict efficacy or safety of the combination.
- TB-500/full-length thymosin β4 identity caveats remain relevant inside the blend.